Angelos Stergiou
1 / 4

Dr. Angelos Stergiou - SELLAS Life Sciences Group - PowerPoint PPT Presentation

  • Uploaded on

Dr. Angelos M. Stergiou, MD, ScD h.c. founded SELLAS Life Sciences Group with Dr. Miltos K. Sugiultzoglu, a friend and colleague.

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'Dr. Angelos Stergiou - SELLAS Life Sciences Group' - AngelosStergiou

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Dr angelos stergiou sellas life sciences group

Angelos Stergiou

About SELLAS Life Sciences Group

Dr angelos stergiou sellas life sciences group

Dr. Angelos M. Stergiou, MD, ScD h.c. is the CEO and Vice Chairman

of SELLAS Life Sciences Group, which he founded with the intention

to give back to humanity through clinical research, discovery and

drug development.

In recent news, Dr. Angelos Stergiou and SELLAS Life Sciences

Group have received increasing media coverage as the progression

of the WT1 neoepitome immunotherapeutic anti-cancer treatment

and vaccine continues to yield promising results.

Dr angelos stergiou sellas life sciences group

The points below will help you learn more about SELLAS Life Chairman

Sciences Group and what the company is contributing to the world:

SELLAS Life Sciences Group. As a leading international

biopharmaceutical company, SELLAS Life Sciences focuses on

advancing various cancer therapies and developing diverse

cancer programs. The company seeks to improve the lives of

patients everywhere by commercializing cutting-edge cancer


WT1 Neoepitope Immunotherapy. Named for the WT1 antigen –

one of the most common antigens found in malignancies – the

WT1 anti-cancer treatment, called galinpepimut-S, consists of

four synthetically heteroclitically modified peptide chains that

are designed to induce patient immune response against the

WT1 antigen. As of 2016, trial phases have shown promising

survival benefits.

Dr angelos stergiou sellas life sciences group

To learn more about the work of SELLAS Life Sciences Group or Dr.

Angelos Stergiou, visit

Also connected with Angelos Stergiou through social profiles: